Sutro Biopharma’s (STRO) Neutral Rating Reiterated at Wedbush

Wedbush reissued their neutral rating on shares of Sutro Biopharma (NASDAQ:STRO) in a report published on Friday,RTT News reports. They currently have a $2.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company decreased their target price on shares of Sutro Biopharma from $4.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Sutro Biopharma in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Sutro Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $4.47.

Sutro Biopharma Trading Up 1.2%

NASDAQ:STRO traded up $0.01 on Friday, reaching $0.83. The stock had a trading volume of 181,664 shares, compared to its average volume of 1,173,774. The company has a 50-day moving average of $0.95 and a 200 day moving average of $0.89. The stock has a market cap of $70.33 million, a P/E ratio of -0.32 and a beta of 1.75. Sutro Biopharma has a 12-month low of $0.52 and a 12-month high of $4.60.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.25). Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The firm had revenue of $9.69 million during the quarter, compared to the consensus estimate of $10.14 million. On average, equities analysts predict that Sutro Biopharma will post -2.92 EPS for the current year.

Insider Transactions at Sutro Biopharma

In other news, Director Connie Matsui bought 50,000 shares of the stock in a transaction on Wednesday, October 15th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $40,000.00. Following the completion of the purchase, the director directly owned 50,000 shares in the company, valued at $40,000. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders acquired 111,754 shares of company stock valued at $89,601. 5.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Cerity Partners LLC purchased a new position in shares of Sutro Biopharma during the 1st quarter valued at about $25,000. Invesco Ltd. grew its position in shares of Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after buying an additional 53,390 shares during the last quarter. Nuveen LLC bought a new position in Sutro Biopharma in the 1st quarter worth $189,000. Affinity Asset Advisors LLC purchased a new stake in Sutro Biopharma in the first quarter worth about $490,000. Finally, State of Wyoming purchased a new stake in Sutro Biopharma in the first quarter worth $62,000. 96.99% of the stock is currently owned by institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.